Components:
Treatment option:
Medically reviewed by Militian Inessa Mesropovna, PharmD. Last updated on 16.03.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Цефтазидим для инъекций is indicated for the treatment of the infections listed below in adults and children including neonates (from birth).
- Nosocomial pneumonia
- Broncho-pulmonary infections in cystic fibrosis
- Bacterial meningitis
- Chronic suppurative otitis media
- Malignant otitis externa
- Complicated urinary tract infections
- Complicated skin and soft tissue infections
- Complicated intra-abdominal infections
- Bone and joint infections
- Peritonitis associated with dialysis in patients on CAPD.
Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Цефтазидим для инъекций may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
Цефтазидим для инъекций may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (TURP).
The selection of Цефтазидим для инъекций should take into account its antibacterial spectrum, which is mainly restricted to aerobic Gram negative bacteria.
Цефтазидим для инъекций should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum of activity.
Consideration should be given to official guidelines on the appropriate use of antibacterial agents.
Posology
Table 1: Adults and children > 40 kg
| Intermittent Administration | |
| Infection | Dose to be administered |
| Broncho-pulmonary infections in cystic fibrosis | 100 to 150 mg/kg/day every 8 h, maximum 9 g per day1 |
| Febrile neutropenia | 2 g every 8 h |
| Nosocomial pneumonia | |
| Bacterial meningitis | |
| Bacteraemia* | |
| Bone and joint infections | 1-2 g every 8 h |
| Complicated skin and soft tissue infections | |
| Complicated intra-abdominal infections | |
| Peritonitis associated with dialysis in patients on CAPD | |
| Complicated urinary tract infections | 1-2 g every 8 h or 12 h |
| Peri-operative prophylaxis for transuretheral resection of prostate (TURP) | 1 g at induction of anaesthesia, and a second dose at catheter removal |
| Chronic suppurative otitis media | 1 g to 2 g every 8h |
| Malignant otitis externa | |
| Continuous Infusion | |
| Infection | Dose to be administered |
| Febrile neutropenia | Loading dose of 2 g followed by a continuous infusion of 4 to 6 g every 24 h1 |
| Nosocomial pneumonia | |
| Broncho-pulmonary infections in cystic fibrosis | |
| Bacterial meningitis | |
| Bacteraemia* | |
| Bone and joint infections | |
| Complicated skin and soft tissue infections | |
| Complicated intra-abdominal infections | |
| Peritonitis associated with dialysis in patients on CAPD | |
| 1 In adults with normal renal function 9 g/day has been used without adverse effects. < | |
Table 2: Children < 40 kg
| Infants and toddlers >2 months and children < 40 kg | Infection | Usual dose |
| Intermittent Administration |
| |
| Complicated urinary tract infections | 100-150 mg/kg/day in three divided doses, maximum 6 g/day | |
| Chronic suppurative otitis media | ||
| Malignant otitis externa | ||
| Neutropenic children | 150 mg/kg/day in three divided doses, maximum 6 g/day | |
| Broncho-pulmonary infections in cystic fibrosis | ||
| Bacterial meningitis | ||
| Bacteraemia* | ||
| Bone and joint infections | 100-150 mg/kg/day in three divided doses, maximum 6 g/day | |
| Complicated skin and soft tissue infections | ||
| Complicated intra-abdominal infections | ||
| Peritonitis associated with dialysis in patients on CAPD | ||
| Continuous Infusion |
| |
| Febrile neutropenia | Loading dose of 60-100 mg/kg followed by a continuous infusion 100-200 mg/kg/day, maximum 6 g/day | |
| Nosocomial pneumonia | ||
| Broncho-pulmonary infections in cystic fibrosis | ||
| Bacterial meningitis | ||
| Bacteraemia* | ||
| Bone and joint infections | ||
| Complicated skin and soft tissue infections | ||
| Complicated intra-abdominal infections | ||
| Peritonitis associated with dialysis in patients on CAPD | ||
| Neonates and infants ≤ 2 months | Infection | Usual dose |
| Intermittent Administration |
| |
| Most infections | 25-60 mg/kg/day in two divided doses1 | |
| 1 In neonates and infants ≤ 2 months, the serum half life of Цефтазидим для инъекций can be three to four times that in adults. | ||
Paediatric population
The safety and efficacy of Цефтазидим для инъекций administered as continuous infusion to neonates and infants ≤ 2 months has not been established.
Elderly
In view of age related reduced clearance of Цефтазидим для инъекций in elderly patients, the daily dose should not normally exceed 3 g in those over 80 years of age.
Hepatic impairment
Available data do not indicate the need for dose adjustment in mild or moderate liver function impairment.). Close clinical monitoring for safety and efficacy is advised.
Renal impairment
Цефтазидим для инъекций is excreted unchanged by the kidneys.).
An initial loading dose of 1 g should be given. Maintenance doses should be based on creatinine clearance:
Table 3: Recommended maintenance doses of Цефтазидим для инъекций in renal impairment - intermittent infusion
Adults and children > 40 kg
| Creatinine clearance (ml/min) | Approx. serum creatinine μmol/l (mg/dl) | Recommended unit dose of Цефтазидим для инъекций (g) | Frequency of dosing (hourly) |
| 50-31 | 150-200 (1.7-2.3) | 1 | 12 |
| 30-16 | 200-350 (2.3-4.0) | 1 | 24 |
| 15-6 | 350-500 (4.0-5.6) | 0.5 | 24 |
| <5 | >500 (>5.6) | 0.5 | 48 |
In patients with severe infections the unit dose should be increased by 50% or the dosing frequency increased.
In children the creatinine clearance should be adjusted for body surface area or lean body mass.
Children < 40 kg
| Creatinine clearance (ml/min)** | Approx. serum creatinine* μmol/l (mg/dl) | Recommended individual dose mg/kg body weight | Frequency of dosing (hourly) |
| 50-31 | 150-200 (1.7-2.3) | 25 | 12 |
| 30-16 | 200-350 (2.3-4.0) | 25 | 24 |
| 15-6 | 350-500 (4.0-5.6) | 12.5 | 24 |
| <5 | >500 (>5.6) | 12.5 | 48 |
| * The serum creatinine values are guideline values that may not indicate exactly the same degree of reduction for all patients with reduced renal function. ** Estimated based on body surface area, or measured. | |||
Close clinical monitoring for safety and efficacy is advised.
Table 4: Recommended maintenance doses of Цефтазидим для инъекций in renal impairment - continuous infusion
Adults and children > 40 kg
| Creatinine clearance (ml/min) | Approx. serum creatinine μmol/l (mg/dl) | Frequency of dosing (hourly) |
| 50-31 | 150-200 (1.7-2.3) | Loading dose of 2 g followed by 1 g to 3 g /24 hours |
| 30-16 | 200-350 (2.3-4.0) | Loading dose of 2 g followed by 1 g/24 hours |
| ≤15 | >350 (>4.0) | Not evaluated |
Caution is advised in dose selection. Close clinical monitoring for safety and efficacy is advised.
Children < 40 kg
The safety and effectiveness of Цефтазидим для инъекций administered as continuous infusion in renally impaired children < 40 kg has not been established. Close clinical monitoring for safety and efficacy is advised.
If continuous infusion is used in children with renal impairment, the creatinine clearance should be adjusted for body surface area or lean body mass.
Haemodialysis
The serum half-life during haemodialysis ranges from 3 to 5 h.
Following each haemodialysis period, the maintenance dose of Цефтазидим для инъекций recommended in the below table should be repeated.
Peritoneal dialysis
Цефтазидим для инъекций may be used in peritoneal dialysis and continuous ambulatory peritoneal dialysis (CAPD).
In addition to intravenous use, Цефтазидим для инъекций can be incorporated into the dialysis fluid (usually 125 to 250 mg for 2 litres of dialysis solution).
For patients in renal failure on continuous arterio-venous haemodialysis or high-flux haemofiltration in intensive therapy units: 1 g daily either as a single dose or in divided doses. For low-flux haemofiltration, follow the dose recommended under renal impairment.
For patients on veno-venous haemofiltration and veno-venous haemodialysis, follow the dosage recommendations in the tables 5 & 6 below.
Table 5: Continuous veno-venous haemofiltration dose guidelines
| Residual renal function (creatinine clearance ml/min) | Maintenance dose (mg) for an ultrafiltration rate (ml/min) of 1: | |||
| 5 | 16.7 | 33.3 | 50 | |
| 0 | 250 | 250 | 500 | 500 |
| 5 | 250 | 250 | 500 | 500 |
| 10 | 250 | 500 | 500 | 750 |
| 15 | 250 | 500 | 500 | 750 |
| 20 | 500 | 500 | 500 | 750 |
| 1 Maintenance dose to be administered every 12 h. | ||||
Table 6: Continuous veno-venous haemodialysis dose guidelines
| Residual renal function (creatinine clearance in ml/min) | Maintenance dose (mg) for a dialysate in flow rate of 1: | ||||||
| 1.0 litre/h | 2.0 litre/h | ||||||
| Ultrafiltration rate (litre/h) | Ultrafiltration rate (litres/h) | ||||||
| 0.5 | 1.0 | 2.0 | 0.5 | 1.0 | 2.0 | ||
| 0 | 500 | 500 | 500 | 500 | 500 | 750 | |
| 5 | 500 | 500 | 750 | 500 | 500 | 750 | |
| 10 | 500 | 500 | 750 | 500 | 750 | 1000 | |
| 15 | 500 | 750 | 750 | 750 | 750 | 1000 | |
| 20 | 750 | 750 | 1000 | 750 | 750 | 1000 | |
| 1 Maintenance dose to be administered every 12 h. | |||||||
Method of administration
The dose depends on the severity, susceptibility, site and type of infection and on the age and renal function of the patient.
Цефтазидим для инъекций should be administered by intravenous injection or infusion, or by deep intramuscular injection. Recommended intramuscular injection sites are the upper outer quadrant of the gluteus maximus or lateral part of the thigh. Цефтазидим для инъекций solutions may be given directly into the vein or introduced into the tubing of a giving set if the patient is receiving parenteral fluids.
The standard recommended route of administration is by intravenous intermittent injection or intravenous continuous infusion. Intramuscular administration should only be considered when the intravenous route is not possible or less appropriate for the patient.
History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams and carbapenems).
Hypersensitivity
As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with Цефтазидим для инъекций must be discontinued immediately and adequate emergency measures must be initiated.
Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to Цефтазидим для инъекций, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if Цефтазидим для инъекций is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.
Spectrum of activity
Цефтазидим для инъекций has a limited spectrum of antibacterial activity. It is not suitable for use as a single agent for the treatment of some types of infections unless the pathogen is already documented and known to be susceptible or there is a very high suspicion that the most likely pathogen(s) would be suitable for treatment with Цефтазидим для инъекций. This particularly applies when considering the treatment of patients with bacteraemia and when treating bacterial meningitis, skin and soft tissue infections and bone and joint infections. In addition, Цефтазидим для инъекций is susceptible to hydrolysis by several of the extended spectrum beta lactamases (ESBLs). Therefore information on the prevalence of ESBL producing organisms should be taken into account when selecting Цефтазидим для инъекций for treatment.
Pseudomembranous colitis
Antibacterial agent-associated colitis and pseudo-membranous colitis have been reported with nearly all anti-bacterial agents, including Цефтазидим для инъекций, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of Цефтазидим для инъекций. Discontinuation of therapy with Цефтазидим для инъекций and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.
Renal function
Concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function.
Цефтазидим для инъекций is eliminated via the kidneys, therefore the dose should be reduced according to the degree of renal impairment. Patients with renal impairment should be closely monitored for both safety and efficacy. Neurological sequelae have occasionally been reported when the dose has not been reduced in patients with renal impairment.
Overgrowth of non-susceptible organisms
Prolonged use may result in the overgrowth of non-susceptible organisms (e.g. Enterococci, fungi) which may require interruption of treatment or other appropriate measures. Repeated evaluation of the patient's condition is essential.
Test and assay interactions
Цефтазидим для инъекций does not interfere with enzyme-based tests for glycosuria, but slight interference (false-positive) may occur with copper reduction methods (Benedict's, Fehling's, Clinitest).
Цефтазидим для инъекций does not interfere in the alkaline picrate assay for creatinine.
The development of a positive Coombs' test associated with the use of Цефтазидим для инъекций in about 5% of patients may interfere with the cross-matching of blood.
Sodium content
Important information about one of the ingredients of Цефтазидим для инъекций:
1 g powder for solution for injection or infusion, 1 g powder for solution for infusion
Цефтазидим для инъекций 1 g contains 2.26mmol of sodium per vial.
This should be considered for patients who are on a controlled sodium diet.
No studies on the effects on the ability to drive and use machines have been performed. However, undesirable effects may occur (e.g. dizziness), which may influence the ability to drive and use machines.
The most common adverse reactions are eosinophilia, thrombocytosis, phlebitis or thrombophlebitis with intravenous administration, diarrhoea, transient increases in hepatic enzymes, maculopapular or urticarcial rash, pain and/or inflammation following intramuscular injection and positive Coomb's test.
Data from sponsored and un-sponsored clinical trials have been used to determine the frequency of common and uncommon undesirable effects. The frequencies assigned to all other undesirable effects were mainly determined using post-marketing data and refer to a reporting rate rather than a true frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. The following convention has been used for the classification of frequency:
Very common (>1/10)
Common (>1/100 to <1/10)
Uncommon (>1/1,000 to <1/100)
Rare (>1/10,000 to <1/1,000)
Very rare (<1/10,000)
Unknown (cannot be estimated from the available data)
| System Organ Class | Common | Uncommon | Very rare | Unknown |
| Infections and infestations | Candidiasis (including vaginitis and oral thrush) | |||
| Blood and lymphatic system disorders | Eosinophilia Thrombocytosis | Neutropenia Leucopenia Thrombocytopenia | Agranulocytosis Haemolytic anaemia Lymphocytosis | |
| Immune system disorders | Anaphylaxis (including bronchospasm and/or hypotension) | |||
| Nervous system disorders | Headache Dizziness | Neurological sequelae1 Paraesthesia | ||
| Vascular disorders | Phlebitis or thrombophlebitis with intravenous administration | |||
| Gastrointestinal disorders | Diarrhoea | Antibacterial agent-associated diarrhoea and colitis2 Abdominal pain Nausea Vomiting | Bad taste | |
| Hepatobiliary disorders | Transient elevations in one or more hepatic enzymes3 | Jaundice | ||
| Skin and subcutaneous tissue disorders | Maculopapular or urticarial rash | Pruritus | Toxic epidermal necrolysis Stevens-johnson syndrome Erythema multiforme Angioedema Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) 4 | |
| Renal and urinary disorders | Transient elevations of blood urea, blood urea nitrogen and/or serum creatinine | Interstitial nephritis Acute renal failure | ||
| General disorders and administration site conditions | Pain and/or inflammation after intramuscular injection | Fever | ||
| Investigations | Positive Coombs' test5 |
1There have been reports of neurological sequelae including tremor, myoclonia, convulsions, encephalopathy and coma in patients with renal impairment in whom the dose of Цефтазидим для инъекций has not been appropriately reduced.
2 Diarrhoea and colitis may be associated with Clostridium difficile and may present as pseudomembranous colitis.
3 ALT (SGPT), AST (SOGT), LHD, GGT, alkaline phosphatase.
4 There have been rare reports where DRESS has been associated with Цефтазидим для инъекций.
5 A positive Coombs test develops in about 5% of patients and may interfere with blood cross matching.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Overdose can lead to neurological sequelae including encephalopathy, convulsion and coma.
Symptoms of overdose can occur if the dose is not reduced appropriately in patients with renal impairment.
Serum levels of Цефтазидим для инъекций can be reduced by haemodialysis or peritoneal dialysis.
Pharmacotherapeutic group: Antibacterials for systemic use. Third-generation cephalosporins ATC code: J01DD02.
Mechanism of action
Цефтазидим для инъекций inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.
PK/PD relationship
For cephalosporins, the most important pharmacokinetic-pharmacodynamic index correlating with in vivo efficacy has been shown to be the percentage of the dosing interval that the unbound concentration remains above the minimum inhibitory concentration (MIC) of Цефтазидим для инъекций for individual target species (i.e. %T>MIC).
Mechanism of Resistance
Bacterial resistance to Цефтазидим для инъекций may be due to one or more of the following mechanisms:
- hydrolysis by beta-lactamases. Цефтазидим для инъекций may be efficiently hydrolysed by extended spectrum beta-lactamases (ESBLs), including the SHV family of ESBLs, and AmpC enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacterial species
- reduced affinity of penicillin-binding proteins for Цефтазидим для инъекций
- outer membrane impermeability, which restricts access of Цефтазидим для инъекций to penicillin binding proteins in Gram-negative organisms.
- bacterial efflux pumps.
Breakpoints
Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:
| Organism | Breakpoints (mg/L) | ||
|
| S
| I | R |
| Enterobacteriaceae | ≤ 1 | 2-4 | > 4 |
| Pseudomonas aeruginosa | ≤ 81 | - | > 8 |
| Non-species related breakpoints2 | ≤4 | 8 | > 8 |
S=susceptible, I=intermediate, R=resistant.
1The breakpoints relate to high dose therapy (2 g x 3).
2Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species not mentioned in the table or footnotes.
Microbiological Susceptibility
The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of Цефтазидим для инъекций in at least some types of infections is questionable
| Commonly Susceptible Species |
| Gram-positive aerobes: Streptococcus pyogenes Streptococcus agalactiae |
| Gram-negative aerobes: Citrobacter koseri Haemophilus influenzae Moraxella catarrhalis Neisseria meningitidis Pasteurella multocida Proteus mirabilis Proteus spp. (other) Providencia spp. |
| Species for which acquired resistance may be a problem |
| Gram-negative aerobes: Acinetobacter baumannii+ Burkholderia cepacia Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Klebsiella pneumoniae Klebsiella spp. (other) Pseudomonas aeruginosa Serratia spp. Morganella morganii |
| Gram-positive aerobes: Staphylococcus aureus£ Streptococcus pneumoniae££ Viridans group streptococcus |
| Gram-positive anaerobes: Clostridium perfringens Peptostreptococcus spp. |
| Gram-negative anaerobes: Fusobacterium spp. |
| Inherently resistant organisms |
| Gram-positive aerobes: Enterococcus spp including Enterococcus faecalis and Enterococcus faecium Listeria spp. |
| Gram-positive anaerobes: Clostridium difficile |
| Gram-negative anaerobes: Bacteroides spp. (many strains of Bacteroides fragilis are resistant). |
| Others: Chlamydia spp. Mycoplasma spp. Legionella spp. |
| £S. aureus that is methicillin-susceptible are considered to have inherent low susceptibility to Цефтазидим для инъекций. All methicillin-resistant S. aureus are resistant to Цефтазидим для инъекций. ££S. pneumoniae that demonstrate intermediate suseptibility or are resistant to penicillin can be expected to demonstrate at least reduced susceptibility to Цефтазидим для инъекций. + High rates of resistance have been observed in one or more areas/countries/regions within the EU. |
Absorption
After intramuscular administration of 500 mg and 1 g of Цефтазидим для инъекций, peak plasma levels of 18 and 37 mg/l, respectively, are achieved rapidly. Five minutes after intravenous bolus injection of 500 mg, 1 g or 2 g, plasma levels are 46, 87 and 170 mg/l, respectively. The kinetics of Цефтазидим для инъекций are linear within the single dose range of 0.5 to 2 g following intravenous or intramuscular dosing.
Distribution
The serum protein binding of Цефтазидим для инъекций is low at about 10%. Concentrations in excess of the MIC for common pathogens can be achieved in tissues such as bone, heart, bile, sputum, aqueous humour, synovial, pleural and peritoneal fluids. Цефтазидим для инъекций crosses the placenta readily, and is excreted in the breast milk. Penetration of the intact blood-brain barrier is poor, resulting in low levels of Цефтазидим для инъекций in the CSF in the absence of inflammation. However, concentrations of 4 to 20 mg/l or more are achieved in the CSF when the meninges are inflamed.
Biotransformation
Цефтазидим для инъекций is not metabolised.
Elimination
After parenteral administration plasma levels decrease with a half-life of about 2 h. Цефтазидим для инъекций is excreted unchanged into the urine by glomerular filtration; approximately 80 to 90% of the dose is recovered in the urine within 24 h. Less than 1% is excreted via the bile.
Special patient populations
Renal impairment
Elimination of Цефтазидим для инъекций is decreased in patients with impaired renal function and the dose should be reduced.
Hepatic impairment
The presence of mild to moderate hepatic dysfunction had no effect on the pharmacokinetics of Цефтазидим для инъекций in individuals administered 2 g intravenously every 8 hours for 5 days, provided renal function was not impaired.
Elderly
The reduced clearance observed in elderly patients was primarily due to age-related decrease in renal clearance of Цефтазидим для инъекций. The mean elimination half-life ranged from 3.5 to 4 hours following single or 7 days repeat BID dosing of 2 g IV bolus injections in elderly patients 80 years or older.
Paediatric population
The half-life of Цефтазидим для инъекций is prolonged in preterm and term neonates by 4.5 to 7.5 hours after doses of 25 to 30 mg/kg. However, by the age of 2 months the half-life is within the range for adults.
Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, repeat dose toxicity, genotoxicity, toxicity to reproduction. Carcinogenicity studies have not been performed with Цефтазидим для инъекций.
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Цефтазидим для инъекций is less stable in Sodium Bicarbonate Injection than other intravenous fluids. It is not recommended as a diluent.
Цефтазидим для инъекций and aminoglycosides should not be mixed in the same giving set or syringe.
Precipitation has been reported when vancomycin has been added to Цефтазидим для инъекций in solution. Therefore, it would be prudent to flush giving sets and intravenous lines between administration of these two agents.
Цефтазидим для инъекций is incompatible with aminophylline. There is a possible incompatibility with pentamide.
For single use. Discard any unused contents.
Instructions for reconstitution: See table for addition volumes and solution concentrations, which may be useful when fractional doses are required.
PREPARATION OF SOLUTION
| INTRAVENOUS | |||||
| Vial size | Diluent | Amount of Diluent to be added (ml) | Approximate Concentration (mg/ml) | Approximate available volume(ml) | Approximate displacement volume(ml) |
| 1g | Water for injection | 10ml | 95 | 10.9ml | 0.9ml |
| Цефтазидим для инъекций may be reconstituted for intramuscular use with 0.5% or 1% Lidocaine Hydrochloride. INTRAMUSCULAR | |||||
| Vial size | Diluent | Amount of Diluent to be added (ml) | Approximate Concentration (mg/ml) | Approximate available volume(ml) | Approximate displacement volume(ml) |
| 1g | 0.5% lidocaine | 3ml | 260 | 3.6ml | 0.6ml |
| 1g | 1% lidocaine | 3ml | 260
| 3.7ml | 0.7ml |
Цефтазидим для инъекций (at the given concentration) has been shown to be compatible with the following diluent solutions:-
Solvents for 40mg/ml Цефтазидим для инъекций concentration:
Sodium Chloride 0.9%
Ringer Solution
Ringer Lactate Solution
Glucose 5%
Glucose 10%
Glucose 5% and Sodium Chloride 0.9%
Glucose 5% and Sodium Chloride 0.45%
Glucose 5% and Sodium Chloride 0.2%
Dextran 40%/10% and Sodium Chloride 0.9%
Dextran 70%/6% and Sodium Chloride 0.9%
Lidocaine Hydrochloride 0.5%
Lidocaine Hydrochloride 1%
Solutions range from light yellow to amber depending on concentration, diluent and storage conditions used.
All sizes of vials as supplied are under reduced pressure. As the product dissolves, carbon dioxide is released and a positive pressure develops. For ease of use, it is recommended that the following technique of reconstitution is adopted.
1. Insert the syringe needle through the vial closure and inject the recommended volume of diluent. The vacuum may assist entry of the diluent. Remove the syringe needle.
2. Shake to dissolve: carbon dioxide is released and a clear solution will be obtained in about 1 to 2 minutes.
3. Invert the vial. With the syringe plunger fully depressed, insert the needle through the vial closure and withdraw the total volume of solution into the syringe (the pressure in the vial may aid withdrawal). Ensure that the needle remains within the solution and does not enter the head space. The withdrawn solution may contain small bubbles of carbon dioxide; they may be disregarded.
These solutions may be given directly into the vein or introduced into the tubing of a giving set if the patient is receiving parental fluids.
